Sharmilan Thanendrarajan

High Impact

Associate Professor

UAMS

Also affiliated: University of Bonn (2011–2012); University Hospital Bonn (2011); University of Arkansas Medical Center (2016–2019); Integrated Oncology (United States) (2011); Cancer Research And Biostatistics (2015); Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie (2011); Myeloma UK (2017–2018); Winthrop Rockefeller Foundation (2020–2025); Netherlands Comprehensive Cancer Organisation (2019); International Myeloma Foundation (2015)

Faculty Researcher

Internal Med, College of Medicine

33 h-index 266 pubs 3,763 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group UAMS TRI Profile

OverviewAI-generated summary

Sharmilan Thanendrarajan, M.D., is an Associate Professor in the Department of Internal Medicine at the University of Arkansas for Medical Sciences, focusing his research on multiple myeloma. His work investigates the molecular underpinnings and evolutionary trajectories of this hematological malignancy, from its precursor stages to relapsed and refractory states. Dr. Thanendrarajan has published research examining the immune microenvironment's role in myeloma progression at a single-cell level and exploring the changing spectrum of infections associated with novel bispecific antibody therapies.

His research also addresses disparities in healthcare access, including geographic and racial inequities in clinical trial enrollment for advanced therapies like CAR-T cells and bispecific antibodies for multiple myeloma. Dr. Thanendrarajan's scholarly contributions are reflected in a high-impact researcher designation, with 263 publications and over 3,600 citations. He leads a research group and collaborates with colleagues at the University of Arkansas for Medical Sciences, including Maurizio Zangari, Carolina Schinke, Samer Al Hadidi, and Frits van Rhee, with whom he shares numerous publications.

Research Overview

Sharmilan Thanendrarajan, M.D., is an Assistant Professor of Medicine with the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences.Dr. Thanendrarajan trained as a fellow in Hematology/Oncology at University Clinic of Bonn in Germany. He trained as a resident in Internal Medicine at University Clinic of Bonn and General Hospital of Hagen. Dr. Thanendrarajan earned his M.D. from the Medical College of Ruhr-University in Bochum, Germany. He is a member of the German Society of Internal Medicine, the German Cancer Society, the German Society for Hematology and Oncology, the European Society for Medical Oncology and the European Myeloma Network. Dr. Thanendrarajan is board certified in Germany in Internal Medicine and Hematology/Oncology. Publications: http://www.ncbi.nlm.nih.gov/pubmed/?term=thanendrarajan+sTo make an appointment with Dr. Thanendrarajan, please call 1-888-MYELOMA.

Metrics

h-index: 33
Publications: 266
Citations: 3,763

Selected Publications

Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)

Blood Cancer Journal 1 citation DOI OpenAlex
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study (2025)

Blood Cancer Journal 14 citations DOI OpenAlex
The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia (2025)

Blood Advances 4 citations DOI OpenAlex
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging (2025)

Blood Advances 1 citation DOI OpenAlex
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)

Cancer Biomarkers 1 citation DOI OpenAlex
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)

JAMA Oncology 6 citations DOI OpenAlex
Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma (2025)

Frontiers in Hematology 1 citation DOI OpenAlex
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma (2025)

Blood Cancer Journal 32 citations DOI OpenAlex
Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma (2025)

Blood Advances 4 citations DOI OpenAlex
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)

Blood Advances 6 citations DOI OpenAlex
Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM) (2024)

Blood 2 citations DOI OpenAlex
Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study (2024)

Blood 8 citations DOI OpenAlex
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024)

Blood 1 citation DOI OpenAlex
Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort (2024)

Blood 3 citations DOI OpenAlex
Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma (2024)

Blood 2 citations DOI OpenAlex